Khai PhamFounder & CEO at ThinkingNode.aiPresenter
Profile
At ThinkingNode, we tackle one of the critical challenges in drug R&D—the unreliable translation of preclinical animal testing to human outcomes. Over 115 million animals are used annually, raising costs, limiting outcomes, and causing ethical issues. Our mission has just been reinforced by FDA announcement: "The FDA’s animal testing requirement will be reduced, refined, or potentially replaced using a range of approaches, including AI-based computational models of toxicity and cell lines and organoid toxicity testing in a laboratory setting (so-called New Approach Methodologies or NAMs data)." Based on a next-gen AI, SMARTNet (Self-organized Multi-Agent Reasoning Technology Network), ThinkingNode can generate at scale human digital cell clones directly from patient biopsy data to predict and understand drug efficacy, specificity, and safety: - Before any animal testing, it allows accurate model selection, compound ranking, lowering trial-error iterations—saving both time and cost. - Combined with animal testing, it provides supplemental human-specific data to strengthen animal study results, ensuring robust and reliable outcomes. Our platform has already demonstrated success in applications with biopharma companies for cancer and autoimmune disorders (IBD). We are looking forward to the possibility of discussing these innovations with partners and investors.